Spectral AI, an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the pricing of a $7.6 million offering. The offering will provide the Company with additional growth capital for the continued expansion and development of its DeepView System.
The transaction includes the issuance of 4,000,000 shares of its common stock and pre-funded warrants at a price of $1.90 per share and corresponding warrants with an exercise price of $2.51 per share of common stock.
Related: VitVio raises $8M for AI-powered OR digitisation tech
J. Michael DiMaio, MD, Chairman of the Board of Spectral AI, said, “I am pleased that we were able to secure institutional funding for Spectral AI. This financing ensures that we can continue to develop and expand the DeepView System’s clinical indications and prepare for commercial readiness in 2026. We remain fully committed to supporting our current BARDA Project BioShield (PBS) contract, while also advancing our AI-powered technology to broaden our product offerings and deliver innovative solutions to the global medical community.”
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. Its DeepView System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.
